The AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical Oncology are urging the Drug Enforcement Agency to allow drug manufacturers and 503B outsourcing facilities to receive increased annual production quota controlled-substance allocations during the COVID-19 crisis.

Doing so, the organizations say in a letter to the DEA, will allow them to meet “legitimate, and absolutely critical, patient care needs” caused by huge spikes in demand for morphine, hydromorphone, fentanyl and other opioids because of the number of patients requiring ventilation

Related News Articles

Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to…
Headline
The Food and Drug Administration yesterday approved the first test to use next generation sequencing technology to detect HIV drug-resistance mutations in…
Headline
Pictured, from left to right: Peter Adamson, chair of the Children’s Oncology Group at the Children’s Hospital of Philadelphia; Brian Marden, chief…
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe…
Headline
The Food and Drug Administration today alerted the public to growing concern about the potential for medical device shortages as facilities that sterilize…